Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, valuing the company at approximately $6.7 billion, or about $5.7 billion net of acquired cash.

默克已达成最终协议，将以每股53.00美元的现金收购Terns Pharmaceuticals，对该公司的估值约为67亿美元，扣除所持现金后净额约为57亿美元。

Chronic myeloid leukaemia is a slow-growing blood cancer characterised by the excessive production of white blood cells. These abnormal cells accumulate in the blood and bone marrow, interfering with normal blood cell production. The disease is commonly linked to the Philadelphia chromosome, a genetic abnormality that produces the BCR::ABL1 fusion protein, which drives cancer progression..

慢性髓性白血病是一种缓慢发展的血液癌症，特征是白细胞的过度生成。这些异常细胞在血液和骨髓中积累，干扰正常血细胞的生成。该疾病通常与费城染色体相关，这是一种产生BCR::ABL1融合蛋白的基因异常，会驱动癌症进展。

TERN-701 is a novel allosteric BCR::ABL1 tyrosine kinase inhibitor currently under evaluation in the Phase 1/2 CARDINAL trial. The study focuses on patients with Philadelphia chromosome-positive chronic phase CML who have previously received at least one tyrosine kinase inhibitor and experienced treatment failure, intolerance, or suboptimal response.

TERN-701 是一种新型的变构 BCR::ABL1 酪氨酸激酶抑制剂，目前正在进行 1/2 期 CARDINAL 试验评估。该研究聚焦于费城染色体阳性慢性期 CML 患者，这些患者之前至少接受过一种酪氨酸激酶抑制剂治疗，但经历了治疗失败、不耐受或次优反应。

The candidate received Orphan Drug Designation from the U.S. Food and Drug Administration in March 2024..

候选药物于2024年3月获得了美国食品药品监督管理局的孤儿药资格认定。

The offer represents a premium of around 31% to the 60-day and 42% to the 90-day volume-weighted average share price as of 24 March 2026.

该报价较2026年3月24日的60日均价溢价约31%，较90日成交量加权平均股价溢价42%。

The acquisition is intended to strengthen Merck’s presence in hematology and expand its oncology pipeline. A key asset in the deal is TERN-701, an investigational oral therapy being developed for chronic myeloid leukaemia (CML).

此次收购旨在加强默克在血液学领域的地位，并扩大其肿瘤学产品线。该交易的关键资产是TERN-701，一种正在开发用于治疗慢性髓性白血病（CML）的口服研究性疗法。

Early clinical findings have shown encouraging results, including notable rates of major and deep molecular responses by week 24. These responses were also observed in patients with high disease burden and those who had undergone multiple prior treatments. Safety data so far suggest that most adverse events are low grade, with few severe cases or treatment discontinuations.

早期临床结果显示出了令人鼓舞的结果，包括在第24周时显著的主要和深度分子反应率。这些反应同样出现在疾病负担较重以及接受过多种前期治疗的患者身上。目前的安全性数据表明，大多数不良事件等级较低，严重病例或治疗中断的情况较少。

No meaningful changes in blood pressure have been reported, and instances of elevated lipase levels have remained low..

据报道，血压没有显著变化，脂肪酶水平升高的情况仍然很少。

The transaction has been approved by the boards of both companies. Under the agreement, Merck will acquire all outstanding shares of Terns through a subsidiary, subject to shareholder approval and customary closing conditions, including regulatory clearance.

该交易已获得两家公司董事会的批准。根据协议，默克将通过一家子公司收购Terns所有已发行股份，但须经股东批准并满足惯例交割条件，包括监管机构的批准。

The deal is expected to close in the second quarter of 2026 and will be accounted for as an asset acquisition. Merck anticipates recording a charge of approximately $5.8 billion, or $2.35 per share, in its 2026 financial results.

该交易预计将于2026年第二季度完成，并将作为资产收购进行核算。默克公司预计将在其2026年财务业绩中记录约58亿美元的费用，合每股2.35美元。

Source: merck.com

来源：merck.com